Imaging intracranial arterial patency and intravenous thrombolysis in acute ischaemic stroke
Files
Item Status
Embargo End Date
Date
Authors
Abstract
Among patients presenting acutely with ischaemic stroke who are being considered
for intravenous thrombolysis, prompt brain imaging is used to exclude contraindications
to treatment (chiefly haemorrhagic stroke or other conditions mimicking
stroke) rather than to identify which patients are more or less likely to benefit from
thrombolysis. For example, it is unclear whether the presence or absence of arterial
obstruction on imaging should be used to guide thrombolysis treatment decisions.
In this thesis I explore methods of imaging arterial patency among patients
presenting acutely with ischaemic stroke and look for associations between these
early imaging findings, response to intravenous thrombolysis and functional outcome
six-months after stroke onset. I primarily use data from the Third International Stroke
Trial (IST-3), the largest ever randomised-controlled trial testing the use of
intravenous alteplase for the acute treatment of ischaemic stroke.
I begin by summarising the main features of stroke, covering techniques for imaging
the brain and for imaging arterial patency, and post-stroke outcomes. Next I describe
two literature reviews which I compiled to increase my understanding of the topic
with particular reference to imaging arterial patency. This is followed by a summary
of IST-3. Then I describe the general methods I used to address my thesis aims
exploring relationships between imaging characteristics of arterial patency, treatment
with intravenous alteplase and functional outcome after ischaemic stroke.
Specifically, I investigated the following imaging features:
- The hyperattenuating artery sign (HAS), which is a non-contrast enhanced
CT finding thought to be indicative of acute arterial obstruction by thrombus
or embolus
- Arterial patency or obstruction as demonstrated using contrast enhanced CT
and MR angiographic imaging.
In addition to providing better characterisation of the HAS and a better
understanding of how angiography helps to assess ischaemic stroke patients, I found
that arterial obstruction (however this is identified on imaging) is associated with more severe stroke at baseline and worse functional outcome six months after stroke.
I also prove that intravenous alteplase is effective in the presence of arterial
obstruction, counter to a widely held concern that it may not be effective in this
context. Most of my work has been published in peer reviewed journals.
My work should give front line clinicians greater confidence to use intravenous
alteplase for the treatment of ischaemic stroke associated with arterial obstruction on
imaging, but more work is needed to better understand the implications of apparently
normal arterial patency on imaging among patients with ischaemic stroke.
This item appears in the following Collection(s)

